[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cordis US Corp.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100611924","mobilization-and-outcomes-after-venous-closure-100611924",false,"NCT07246902","Mobilization and Outcomes After Venous Closure","MOVE - Mobilization and Outcomes After VEnous Closure - A Prospective Registry of Real-World Outcomes\u002FUsage\u002FEvidence for the MYNX CONTROL™ VENOUS Vascular Closure Device 6F-12F","MOVE","Inclusion Criteria\n\n1. Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.\n2. Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.\n3. Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.\n4. At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events\u002Fcomplications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).\n\nExclusion Criteria\n\n1. Presence of bruit, palpable aneurysm, significant candida or groin infection.\n2. Prior to closure, presence of hematoma in the accessed limb.\n3. Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.\n4. Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.\n5. Life expectancy \\\u003C12 months.","ALL",{"count":19,"type":20},300,"ESTIMATED","14 Days","OBSERVATIONAL","The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.",[25,26],"Venous Vascular Closure","Electrophysiology Study",[26,28,29,30,25,31,32,33,15,34,35],"Venous closure","Venous access closure","Vascular access closure","Vascular closure device","MYNX CONTROL VENOUS","MOVE Registry","Cardiac Catheterization","MYNX","RECRUITING","2026-03-13",{"date":39,"type":40},"2026-03-16","ACTUAL",{"date":42,"type":40},"2025-11-24",{"date":44,"type":20},"2026-08",{"name":46,"class":47},"Cordis US Corp.","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100618997","post-market-clinical-follow-up-of-smart-family-of-stents-in-treating-iliac-and-femoropopliteal-artery-disease-100618997","NCT07338890","Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease","Post-Market Clinical Follow-Up Study of the S.M.A.R.T.™ Nitinol Stent System, S.M.A.R.T.™ CONTROL™ Nitinol Stent System and S.M.A.R.T. ™ Flex Vascular Stent System in the Treatment of Iliac and Femoropopliteal Artery Disease (REAL-SMART)","REAL-SMART","Inclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to include in the study:\n\n* Subjects treated with SMART 120\u002F150, SMART CONTROL or SMART Flex according to the respective Instructions for Use for treatment in the iliac, superficial femoral and\u002For proximal popliteal arteries.\n* If an EC-approved informed consent waiver is not obtained, then documented informed consent from the subject or legal representative granting permission to share the subject's clinical data It is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment\u002Fprocedure or until time of death, whichever came first.\n\nIt is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment\u002Fprocedure or until time of death, whichever came first. Subjects not included because follow-up information is unavailable will be documented, wherever possible, with respect to demographics and presenting disease state to determine whether they are similar to subjects with follow-up that are enrolled.\n\nExclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to exclude in the study:\n\n* Women who were pregnant or lactating at the time of the procedure.\n* Pediatric subjects (\\\u003C18 years of age) at the time of the procedure.","18 Years",{"count":58,"type":20},240,"The purpose of this study is to evaluate long-term safety and performance per the intended use of the S.M.A.R.T.™ Nitinol Stent System (SMART 120\u002F150), S.M.A.R.T.™ CONTROL™ Nitinol Stent System (SMART CONTROL) and S.M.A.R.T.™ Flex Vascular Stent System (SMART Flex) in the treatment of iliac and femoropopliteal artery disease.",[61,62,63],"Superficial Femoral Artery Stenosis","Iliac Artery Stenosis","Popliteal Artery Stenosis",[61,62,63,65,66,67,68,69],"SMART CONTROL Nitinol Stent System","SMART FLEX Vascular Stent System","SMART Nitinol Stent System","SFA Stenosis","PPA Stenosis","NOT_YET_RECRUITING","2026-01-04",{"date":73,"type":40},"2026-01-14",{"date":75,"type":20},"2026-01-31",{"date":77,"type":20},"2026-05-30",{"name":46,"class":47},1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100602362","post-approval-study-of-palmaz-mullins-xd-in-treating-pulmonary-artery-stenosis-100602362","NCT07122518","Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis","A Post-Approval Evaluation of the PALMAZ MULLINS XD™ Pulmonary Stent in the Treatment of Pulmonary Artery Stenosis (REALPASS)","REALPASS","\\- Subjects \\*should\\* meet criteria as per the list of indications\u002Fcontraindications in the Instructions for Use, though all subjects treated with PALMAZ MULLINS XD™ Pulmonary Stent will be considered eligible and enrolled.","21 Years",{"count":90,"type":20},75,"The purpose of the clinical investigation is to characterize clinical outcomes and to assess the real-world use of the commercial PALMAZ MULLINS XD™ Pulmonary Stent.",[93],"Pulmonary Artery Stenosis",[95,96,97],"pulmonary artery stenosis","Pulmonary Artery Stenting","PALMAZ MULLINS XD Pulmonary Stent","2025-08-07",{"date":100,"type":40},"2025-08-14",{"date":102,"type":20},"2025-12",{"date":104,"type":20},"2027-12",{"name":46,"class":47},""]